Navigation Links
Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
Date:6/26/2009

OSLO, Norway, June 26 /PRNewswire-FirstCall/ -- Clavis Pharma ASA (OSE: CLAVIS) today announced that the Company has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK 12.00 per share (the "Private Placement").

The Private Placement took place through a bookbuilding process and was managed by Carnegie ASA and DnB NOR Markets as joint-lead managers and joint bookrunners. The Private Placement, which represents approximately 80% of the current outstanding share capital, was well oversubscribed at the issue price and was supported by existing life science and institutional investors, including NeoMed Management and MVM Life Science Partners, as well as new institutional investors.

The net proceeds to the Company from the Private Placement will provide financial resources to achieve key clinical data on its products in development, and optimise its commercial strategy. More specifically, the Company intends to use the net proceeds to:

    i)  Obtain randomised data from clinical studies for lead products
         a. Complete first part of a Phase II/III registration study for
            elacytarabine in leukaemia (AML)
         b. Complete a randomised Phase II study with IV CP-4126 in
            pancreatic cancer
         c. Complete Phase I study for Oral CP-4126 in various solid cancers
    ii)  Achieve pre-clinical proof of concept for CP-4200
    iii) Place the company in a position of strength from which to negotiate
         appropriate partnership agreements as well as for general corporate
         purposes

Completion of the Private Placement is conditional upon approval by the Company's Extraordinary General Meeting to be held on or about 15 July 2009 (the "EGM"). Shareholders representing more than the required two thirds of the shares
'/>"/>

SOURCE Clavis Pharma ASA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal ... been selected by Buffalo BioBlower Technologies LLC ("B3") as ... SBIR Phase 2 award from the Army Corps of ... system that kills all biological contaminants and destroys VOCs ...
(Date:1/15/2014)... JOSE, California , January 15, 2014 ... cancer, today announced the appointment of Thomas C Reynolds MD, ... 20 years, development experience gained in the biotechnology industry, most ... "I am delighted to welcome Tom at this transformative time ...
(Date:1/15/2014)... , January 15, 2014 A study ... races on the Formula 1 track could help to tackle ... Applied Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) ... healthcare provider Simplyhealth. Telemetry technology, which is inspired ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... ... ... -- MODA Technology Partners will offer a live, interactive Webinar on the benefits and value ... 9:00 AM MT). The presentation will feature Marvin Thompson, Manager, Quality Operations at Talecris, and ...
... U.S. Department of Energy,s Argonne National Laboratory will ... in Electrochemical Energy Storage Beyond Lithium Ion: Computational ... electronics and renewable energy applications. Registration ... next generation of high-performance battery technologies is likely ...
... ... MM-111 breast cancer study in combination with trastuzumab. , ... Cambridge, MA (PRWEB) April 17, 2010 -- Merrimack ... the two lead candidates in the company’s pipeline of five novel cancer antibodies, at ...
Cached Biology Technology:Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics 2Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics 3Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR) 2Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR) 3
(Date:7/9/2014)... Calif. Sexual selection refers to species, selection for ... special type of natural selection enhances opportunities to mate, ... , Biologists at the University of California, Riverside have ... formation of a placenta are linked. Describing the ... in the family Poeciliidae, the researchers found that species ...
(Date:7/9/2014)... nature,s ability to split the water molecule during ... artificial photosynthesis for clean, green and renewable energy ... scientists led by researchers with the Lawrence Berkeley ... Accelerator Laboratory. , Working at SLAC,s Linac ... x-ray laser, the researchers were able to take ...
(Date:7/9/2014)... studying critically ill children with traumatic injuries have ... are likely to develop a hospital-acquired infection. The ... and published online in June in the journal ... efforts that could lead to the clinical implementation ... prevent or reverse immune system damage following critical ...
Breaking Biology News(10 mins):Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... lesson or two from tiny cells on how to maximize ... at Chicago have found that intra-cellular trafficking is tightly coordinated ... on a crowded road are allowed to pass quickly through ... molecular mechanism that underlies this coordination is reported by lead ...
... for over 50 years that moths can hear the ultrasonic ... are among the simplest in the insect world—they have only ... Previously, it was thought that these ears were only partially ... it would seem likely that by using high ultrasound, bats ...
... a medical case of Jekyll and Hyde, carbon monoxide ... faulty heating systems ?has proven effective in treating the ... condition that typically leads to right heart failure and ... animal study led by researchers at Beth Israel Deaconess ...
Cached Biology News:Molecular mechanism provides intra-cellular traffic signal 2Therapeutic role found for carbon monoxide 2Therapeutic role found for carbon monoxide 3
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... kit contains 5 ml CELLection Dynabeads (4.5 ... the human epithelial antigen EpCAM and DNase ... log enrichment of epithelial tumour cells directly ... cells clumps can be enriched from bone ...
... Cy3 Ab Labeling Kit, 1 kit. ... with CyDye fluorescent dyes. Conjugations are ... complete within 1 h. Dyes are ... to ensure consistent labelings. Category: Blotting ...
PHOTOMAN DIRECT COPY CAMERA, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: